Sobi

NICE publishes guidance in England & Wales recommending Altuvoct (efanesoctocog alfa) as a treatment option for people with severe haemophilia A aged 2 years and over

2 April 2025 -- Stockholm, Sweden -- Sobi in the UK today announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England and Wales recommending the use of Altuvoct (efanesoctocog alfa).  The high-sustained factor VIII replacement therapy will now be available for treating and preventing bleeding episodes...
Norra Stationsgatan 93A Stockholm

+46(0)8 697 20 00